Aflibercept Drug Aliquot | Anti-VEGF-A/PIGF | Therapeutic Fusion Protein

Aliquoted from the original reference drug | Now available for research use

Aliquots of the reference drug Aflibercept are now available as research consumables.

Aflibercept drug aliquots can be used for in vitro or in vivo experiments. For biosimilar development, different batches of Aflibercept drug can be ordered at the same time. Several other reference drugs are also available. The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.

Not looking for Aflibercept Reference Drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Eylea® / Aflibercept Reference Product

Drug nameEylea®
API typeFusion protein consisting of portions of human VEGF (Vascular Endothelial Growth Factor) receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology
Pharmacotherapeutic group
Ophthalmologicals / Antineovascularisation agents
ATC code
Target of antibody
Vascular endothelial growth factor A (VEGF-A) and placental growth factor (PlGF)
General functionAflibercept is an engineered protein that has been designed to attach to and block the effects of a substance called vascular endothelial growth factor A (VEGF-A). It can also attach to other proteins such as placental growth factor (PlGF). VEGF-A and PlGF are involved in stimulating the abnormal growth of blood vessels in patients with AMD, certain types of macular oedema and myopic choroidal neovascularisation. By blocking these factors, aflibercept reduces the growth of the blood vessels and controls the leakage and swelling.
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptor 1 and 2 extracellular domains fused to the Fc portion of human IgG1. Aflibercept acts as a soluble decoy receptor that binds VEGF-A and PlGF with higher affinity than their natural receptors, and thereby can inhibit the binding and activation of these cognate VEGF receptors.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)Wet AMD is characterised by pathological choroidal neovascularisation (CNV). Leakage of blood and fluid from CNV may cause retinal thickening or oedema and/or sub-/intra-retinal haemorrhage, resulting in loss of visual acuity. In patients treated with Eylea, central retinal thickness [CRT] decreased soon after treatment initiation, and the mean CNV lesion size was reduced.
Original license holder
Bayer AG
Müllerstraße 178
13353 Berlin
Marketing authorisation numbers
Marketing authorisation holder
Bayer AG
51368 Leverkusen
Name of the manufacturer of the biological active substance
Regeneron Pharmaceuticals, Inc. 81 Columbia Turnpike Rensselaer, New York 12144 USA
Name and address of the manufacturer(s) responsible for batch releaseBayer AG
Müllerstraße 178
13353 Berlin
Max shelf life
24 months
Storage conditions
2°C – 8°C
List of excipients
Polysorbate 20
Sodium dihydrogen phosphate, monohydrate
Disodium hydrogen phosphate, heptahydrate
Sodium chloride

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.